°£Æí°áÁ¦, ½Å¿ëÄ«µå û±¸ÇÒÀÎ
ÀÎÅÍÆÄÅ© ·Ôµ¥Ä«µå 5% (128,250¿ø)
(ÃÖ´ëÇÒÀÎ 10¸¸¿ø / Àü¿ù½ÇÀû 40¸¸¿ø)
ºÏÇǴϾð ·Ôµ¥Ä«µå 30% (105,000¿ø)
(ÃÖ´ëÇÒÀÎ 3¸¸¿ø / 3¸¸¿ø ÀÌ»ó °áÁ¦)
NH¼îÇÎ&ÀÎÅÍÆÄÅ©Ä«µå 20% (108,000¿ø)
(ÃÖ´ëÇÒÀÎ 4¸¸¿ø / 2¸¸¿ø ÀÌ»ó °áÁ¦)
Close

¾àó¹æÀÇ Á¤¼®: Drug Class Review & Real World ¼¼Æ®

¼Òµæ°øÁ¦

2013³â 9¿ù 9ÀÏ ÀÌÈÄ ´©Àû¼öÄ¡ÀÔ´Ï´Ù.

ÆǸÅÁö¼ö 1,482
?
ÆǸÅÁö¼ö¶õ?
»çÀÌÆ®ÀÇ ÆǸŷ®¿¡ ±â¹ÝÇÏ¿© ÆǸŷ® ÃßÀ̸¦ ¹Ý¿µÇÑ ÀÎÅÍÆÄÅ© µµ¼­¿¡¼­ÀÇ µ¶¸³ÀûÀÎ ÆǸŠÁö¼öÀÔ´Ï´Ù. ÇöÀç °¡Àå Àß Æȸ®´Â »óÇ°¿¡ °¡ÁßÄ¡¸¦ µÎ¾ú±â ¶§¹®¿¡ ½ÇÁ¦ ´©Àû ÆǸŷ®°ú´Â ´Ù¼Ò Â÷ÀÌ°¡ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ÆǸŷ® ¿Ü¿¡µµ ´Ù¾çÇÑ °¡ÁßÄ¡·Î ±¸¼ºµÇ¾î ÃÖ±ÙÀÇ À̽´µµ¼­ È®Àνà À¯¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇØ´ç Áö¼ö´Â ¸ÅÀÏ °»½ÅµË´Ï´Ù.
Close
°øÀ¯Çϱâ
Á¤°¡

150,000¿ø

  • 135,000¿ø (10%ÇÒÀÎ)

    1,500P (1%Àû¸³)

ÇÒÀÎÇýÅÃ
Àû¸³ÇýÅÃ
  • S-Point Àû¸³Àº ¸¶ÀÌÆäÀÌÁö¿¡¼­ Á÷Á¢ ±¸¸ÅÈ®Á¤ÇϽŠ°æ¿ì¸¸ Àû¸³ µË´Ï´Ù.
Ãß°¡ÇýÅÃ
¹è¼ÛÁ¤º¸
  • 4/20(Åä) À̳» ¹ß¼Û ¿¹Á¤  (¼­¿ï½Ã °­³²±¸ »ï¼º·Î 512)
  • ¹«·á¹è¼Û
ÁÖ¹®¼ö·®
°¨¼Ò Áõ°¡
  • À̺¥Æ®/±âȹÀü

  • ¿¬°üµµ¼­

  • »óÇ°±Ç

AD

Ã¥¼Ò°³

¡º¾àó¹æÀÇ Á¤¼®: Drug Class Review & Real World ¼¼Æ®¡»´Â ´Ü¼øÈ÷ ¾à¿¡ ´ëÇÑ Á¤º¸¸¸À» Á¦°øÇϱâ À§ÇÑ Ã¥Àº ¾Æ´Õ´Ï´Ù. ¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ¿¡¼­ ÇÑ¹ß ´õ ³ª¾Æ°¡ °¡À̵å¶óÀÎÀ̳ª ±Ù°Å ±â¹ÝÀ¸·Î ¾àÀ» ó¹æÇÏ´Â ½ÇÀüÁöħÀ» Á¦½ÃÇÏ´Â °ÍÀÌ ÀÌ Ã¥ÀÇ ±Ã±ØÀûÀÎ ÁöÇâÁ¡ÀÔ´Ï´Ù. ÀÌ°ÍÀÌ ¹Ù·Î "Real world prescription"À̶ó´Â ºÎÁ¦¿¡ ´ã±ä ÀǹÌÀÔ´Ï´Ù.

¸ñÂ÷

Vol. 1

PART 1. ¿©·¯ °èÅë¿¡ µÎ·ç »ç¿ëµÇ´Â ¾à¹°

Chapter 01. ÀÚÀ²½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°
Topic 1. ÀÚÀ²½Å°æ°è -------- -------- 4
Topic 2. Äݸ° ¾à¹° -------- -------- 11
2-1. Äݸ° ÀÛ¿ëÁ¦ -------- 11
2-2. Äݸ° ±æÇ×Á¦ -------- 16
Topic 3. ¾Æµå·¹³¯¸° ¾à¹° -------- 21
3-1. ¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦ -------- 21
3-2. ¾Æµå·¹³¯¸° ±æÇ×Á¦ -------- 30

Chapter 02. Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å·ù
[SPECIAL REVIEW] Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å: °³¿ä -------- 38
Topic 4. NSAIDs -------- 42
Topic 5. Leukotriene Á¶ÀýÁ¦ -------- 49
Topic 6. ½ºÅ×·ÎÀ̵å -------- 53

Chapter 03. È÷½ºÅ¸¹Î/¼¼·ÎÅä´Ñ/Prostagladin
Topic 7. È÷½ºÅ¸¹Î/Ç×È÷½ºÅ¸¹ÎÁ¦ -------- 60
Topic 8. ¼¼·ÎÅä´Ñ -------- 71
Topic 9. Prostagladin -------- 77

Chapter 04. ÁøÅëÁ¦/ÅëÁõÄ¡·á
Topic 10. Non-opioid -------- 85
Topic 11. Opioid -------- 88
Topic 12. ¾Ï¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 97
Topic 13. ½Å°æº´¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 109

Chapter 05. Ç×»ýÁ¦/Ç×¾ÏÁ¦/¸é¿ª¾ïÁ¦Á¦
Topic 14. Ç×»ýÁ¦ -------- 124
Topic 15. Ç×¾ÏÁ¦ -------- 140
15-1. ¼¼Æ÷µ¶¼ºÇ×¾ÏÁ¦/¹é±Ý -------- 142
15-2. Ç×´ë»çÁ¦ -------- 144
15-3. Ç×¾Ï Ç×»ý¾à -------- 154
15-4. Plant alkaloid -------- 156
15-5. Ç¥ÀûÇ×¾ÏÁ¦ -------- 161
15-6. ¸é¿ªÇ×¾ÏÁ¦ -------- 164
Topic 16. ¸é¿ª¾ïÁ¦Á¦/¸é¿ªÁ¶ÀýÁ¦ -------- 167

PART 2. ½ÉÇ÷°ü/½ÅÀå
Chapter 01. [Drug Class Review] ½ÉÇ÷°ü/½ÅÀå¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÀÌ´¢Á¦(Diuretics) -------- 176
Topic 2. º£Å¸Â÷´ÜÁ¦(Beta blocker) -------- 195
Topic 3. Ä®½·Â÷´ÜÁ¦(Calcium channel blockers, calcium antagonists) -------- 208
Topic 4. ACEI & ARB -------- 221
Topic 5. Ç×Ç÷ÀüÁ¦(Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦, Ç÷Àü¿ëÇØÁ¦) -------- 236
5-1. Ç×Ç÷¼ÒÆÇÁ¦(Antiplatelet agents) -------- 236
5-2. Ç×ÀÀ°íÁ¦(Anticoagulants) -------- 249
5-3. Ç÷Àü¿ëÇØÁ¦(Thrombolytics) -------- 262
Topic 6. Ç÷°üÈ®ÀåÁ¦ -------- 264

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 10. °íÇ÷¾Ð(Hypertension) -------- 274
Topic 11. ºÎÁ¤¸Æ -------- 287
11-1. Ç׺ÎÁ¤¸ÆÁ¦ -------- 287
11-2. ºÎÁ¤¸ÆÀÇ ¾à¹°¿ä¹ý: Overview -------- 301
Topic 12. ½ÉºÎÀü -------- 302
[SPECIAL REVIEW] ARNI (Angiotensin Receptor Neprilysin Inhibitor) -------- 340
Topic 13. ÇãÇ÷¼º ½ÉÁúȯ -------- 348
[SUPPLEMENT] ÇãÇ÷¼º ½ÉÁúȯ ¿ä¾à -------- 351

PART 3. Ç÷¾×
Chapter 01. [Drug Class Review] Ç÷¾×°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. Ç÷¾×Á¦Á¦ -------- 384
Topic 2. ÁöÇ÷Á¦Á¦ -------- 389
Topic 3. Á¶Ç÷¼ºÀåÀÎÀÚ -------- 397

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ö°áÇ̺óÇ÷ -------- 406
Topic 5. °Å´ëÀûÇ÷¸ð±¸ºóÇ÷ -------- 418
Topic 6. ¸é¿ªÇ÷¼ÒÆÇ°¨¼ÒÁõ -------- 424

PART 4. È£Èí±â/¾Ë·¹¸£±â
Chapter 01. [Drug Class Review] È£Èí±â/¾Ë·¹¸£±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÁøÇØ°Å´ãÁ¦ -------- 436
1-1. ÁøÇØÁ¦ -------- 436
1-2. °Å´ãÁ¦ -------- 442
Topic 2. ±â°üÁöÈ®ÀåÁ¦ -------- 453
Topic 3. ±¹¼Ò ½ºÅ×·ÎÀ̵å: ÈíÀÔ ½ºÅ×·ÎÀ̵å -------- 462

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ¸¸¼º ±âħ -------- 468
[SUPPLEMENT] ¸¸¼º ±âħ: ÁÖ¿ä ¿øÀÎ Áúȯº° Ä¡·á -------- 475
Topic 5. ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD) -------- 484
[SUPPLEMENT] GOLD °¡À̵å¶óÀÎÀÇ º¯È­ -------- 496
[SUPPLEMENT] ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD): ±Þ¼º¾ÇÈ­ -------- 503
[SUPPLEMENT] Phosphodiesterase4 (PDE4) ¾ïÁ¦Á¦ -------- 514
Topic 6. õ½Ä(Asthma) -------- 516
Topic 7. ¾Ë·¹¸£±â ºñ¿°(Allergic rhinitis) -------- 529

PART 5. ¼ÒÈ­±â
Chapter 01. [Drug Class Review] ¼ÒÈ­±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. À§½Äµµ¿ª·ùÁúȯ/¼ÒÈ­¼º ±Ë¾ç Ä¡·áÁ¦ -------- 552
1-1. ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(Proton pump inhibitor, PPI) -------- 558
1-2. À§»êºÐºñ¾ïÁ¦Á¦: Potassium-Competitive Acid Blockers(PCAB) -------- 572
1-3. À§»êºÐºñ¾ïÁ¦Á¦: Histamine-2 receptor antagonist(H2RA) -------- 577
1-4. Á¦»êÁ¦ -------- 585
1-5. Á¡¸·º¸È£Á¦(Coating agents)/±âŸ ¹æ¾îÀÎÀÚ Áõ°­¾àÁ¦ -------- 591
Topic 2. À§Àå°ü¿îµ¿ÃËÁøÁ¦(Prokinetics) -------- 599
Topic 3. Ç×±¸ÅäÁ¦(Anti-emetics) -------- 610
Topic 4. Áö»çÁ¦(Anti-diarrheal agents) -------- 623
Topic 5. º¯ºñ, ¿ÏÇÏÁ¦ -------- 629

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 6. ½Ä¿åºÎÁø/½Ä¿åÃËÁøÁ¦(appetite stimulants) -------- 644
Topic 7. ¸¸¼º º¯ºñ -------- 647
Topic 8. À§½Äµµ¿ª·ùÁúȯ -------- 650
Topic 9. ¼ÒÈ­¼º ±Ë¾ç/Ç︮ÄÚ¹ÚÅÍ °¨¿° -------- 664
[SUPPLEMENT] ¼ÒÈ­¼º ±Ë¾ç: NSAIDs ¿¬°ü ±Ë¾ç -------- 668
Topic 10. ±â´É¼º À§ÀåÀå¾Ö -------- 683
10-1. ±â´É¼º ¼ÒÈ­ºÒ·®Áõ -------- 683
10-2. °ú¹Î´ëÀåÁõÈıº -------- 692
Topic 11. ¿°Áõ¼º ÀåÁúȯ -------- 706
[SPECIAL REVIEW] ±Ë¾ç¼º ´ëÀå¿° vs. Å©·Ðº´ -------- 709
Topic 12. ¸¸¼º BÇü °£¿° -------- 725
Topic 13. ¸¸¼º CÇü °£¿° -------- 734
[SPECIAL REVIEW] Pan-genotypic DAA regimens -------- 745

Vol. 2

PART 6. ³»ºÐºñ

Chapter 01. [Drug Class Review] ³»ºÐºñ¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ºÎ½Å°ÑÁú È£¸£¸ó/±æÇ×Á¦ -------- 4
Topic 2. »ý½Ä»ù È£¸£¸ó/±æÇ×Á¦ -------- 6
2-1. »ý½Ä»ù È£¸£¸ó -------- 6
2-2. »ý½Ä»ù È£¸£¸ó ±æÇ×Á¦ -------- 18

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 3. °©»ó»ù Áúȯ -------- 32
3-1. °©»ó»ù ±â´ÉÀúÇÏÁõ -------- 32
[Âü°í] °©»ó»ù ÁúȯÀ» ÀÌÇØÇϱâ À§ÇÑ ±âÃÊ -------- 32
3-2. °©»ó»ù ±â´ÉÇ×ÁøÁõ -------- 42
Topic 4. ´ç´¢º´ -------- 52
4-1. ´ç´¢º´: Ä¡·á ¹× ¾à¹°¿ä¹ý Overview -------- 52
4-2. ´ç´¢º´: ¾à¹°¿ä¹ý-°æ±¸Ç÷´ç°­ÇÏÁ¦ -------- 78
[SUPPLEMENT] Incretin °ü·Ã ¾à¹° -------- 87
4-3. ´ç´¢º´: ¾à¹°¿ä¹ý-ÁÖ»çÁ¦ -------- 96
Topic 5. ÀÌ»óÁöÁúÇ÷Áõ -------- 103
[SPECIAL REVIEW] PCSK9 (Proprotein convertase subtilisin-kexin type 9) ¾ïÁ¦Á¦ -------- 120
Topic 6. ºñ¸¸ -------- 121
[SPECIAL REVIEW] GLP-1 agonist: Liraglutide (Saxenda) -------- 130
Topic 7. °ñ´Ù°øÁõ -------- 142
[SPECIAL REVIEW] °ñ´Ù°øÁõ: ¾à¹°¿ä¹ý: Denosumab (RANKL ´ÜÀÏŬ·ÐÇ×ü) -------- 161
Topic 8. Æó°æ(¿©¼º°»³â±â ÁõÈıº) -------- 178
Topic 9. ³²¼º°»³â±â ÁõÈıº -------- 185

PART 7. ¿ä·Î»ý½Ä±â
Chapter 01. [Drug Class Review] ¿ä·Î»ý½Ä±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö¿¡ »ç¿ëµÇ´Â ¾à¹° -------- 197

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 2. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö -------- 198
2-1. Àü¸³¼±ºñ´ëÁõ -------- 198
2-2. °ú¹Î¼º ¹æ±¤ -------- 215
[SPECIAL REVIEW] °ú¹Î¼º¹æ±¤: ¾à¹°¿ä¹ý: º£Å¸3 ¾Æµå·¹³¯¸° ¼ö¿ëü ÀÛ¿ëÁ¦: mirabegron -------- 220
2-3. ¿ä½Ç±Ý -------- 226
Topic 3. ³²¼º ¼º±â´ÉÀå¾Ö -------- 234
3-1. ¹ß±âºÎÀü -------- 234
3-2. Á¶·çÁõ -------- 246

PART 8. ½Å°æ/Á¤½Å
Chapter 01. [Drug Class Review] ½Å°æ/Á¤½Å°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. GABA ¹× Glutamate¼º ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 256
[Âü°í] GABA/Glutamate -------- 256
1-1. Benzodiazepine -------- 258
1-2. Barbiturate -------- 269
1-3. Ç׳úÀüÁõÁ¦ -------- 275
[SPECIAL REVIEW] Gabapentenoids: gaba

Vol. 1

PART 1. ¿©·¯ °èÅë¿¡ µÎ·ç »ç¿ëµÇ´Â ¾à¹°
Chapter 01. ÀÚÀ²½Å°æ°è¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°
Topic 1. ÀÚÀ²½Å°æ°è -------- -------- 4
Topic 2. Äݸ° ¾à¹° -------- -------- 11
2-1. Äݸ° ÀÛ¿ëÁ¦ -------- 11
2-2. Äݸ° ±æÇ×Á¦ -------- 16
Topic 3. ¾Æµå·¹³¯¸° ¾à¹° -------- 21
3-1. ¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦ -------- 21
3-2. ¾Æµå·¹³¯¸° ±æÇ×Á¦ -------- 30

Chapter 02. Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å·ù
[SPECIAL REVIEW] Ç׿°ÁõÁ¦/¿ÀŸÄÚÀ̵å: °³¿ä -------- 38
Topic 4. NSAIDs -------- 42
Topic 5. Leukotriene Á¶ÀýÁ¦ -------- 49
Topic 6. ½ºÅ×·ÎÀ̵å -------- 53

Chapter 03. È÷½ºÅ¸¹Î/¼¼·ÎÅä´Ñ/Prostagladin
Topic 7. È÷½ºÅ¸¹Î/Ç×È÷½ºÅ¸¹ÎÁ¦ -------- 60
Topic 8. ¼¼·ÎÅä´Ñ -------- 71
Topic 9. Prostagladin -------- 77

Chapter 04. ÁøÅëÁ¦/ÅëÁõÄ¡·á
Topic 10. Non-opioid -------- 85
Topic 11. Opioid -------- 88
Topic 12. ¾Ï¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 97
Topic 13. ½Å°æº´¼º ÅëÁõÀÇ ¾à¹°¿ä¹ý -------- 109

Chapter 05. Ç×»ýÁ¦/Ç×¾ÏÁ¦/¸é¿ª¾ïÁ¦Á¦
Topic 14. Ç×»ýÁ¦ -------- 124
Topic 15. Ç×¾ÏÁ¦ -------- 140
15-1. ¼¼Æ÷µ¶¼ºÇ×¾ÏÁ¦/¹é±Ý -------- 142
15-2. Ç×´ë»çÁ¦ -------- 144
15-3. Ç×¾Ï Ç×»ý¾à -------- 154
15-4. Plant alkaloid -------- 156
15-5. Ç¥ÀûÇ×¾ÏÁ¦ -------- 161
15-6. ¸é¿ªÇ×¾ÏÁ¦ -------- 164
Topic 16. ¸é¿ª¾ïÁ¦Á¦/¸é¿ªÁ¶ÀýÁ¦ -------- 167

PART 2. ½ÉÇ÷°ü/½ÅÀå
Chapter 01. [Drug Class Review] ½ÉÇ÷°ü/½ÅÀå¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÀÌ´¢Á¦(Diuretics) -------- 176
Topic 2. º£Å¸Â÷´ÜÁ¦(Beta blocker) -------- 195
Topic 3. Ä®½·Â÷´ÜÁ¦(Calcium channel blockers, calcium antagonists) -------- 208
Topic 4. ACEI & ARB -------- 221
Topic 5. Ç×Ç÷ÀüÁ¦(Ç×Ç÷¼ÒÆÇÁ¦, Ç×ÀÀ°íÁ¦, Ç÷Àü¿ëÇØÁ¦) -------- 236
5-1. Ç×Ç÷¼ÒÆÇÁ¦(Antiplatelet agents) -------- 236
5-2. Ç×ÀÀ°íÁ¦(Anticoagulants) -------- 249
5-3. Ç÷Àü¿ëÇØÁ¦(Thrombolytics) -------- 262
Topic 6. Ç÷°üÈ®ÀåÁ¦ -------- 264

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 10. °íÇ÷¾Ð(Hypertension) -------- 274
Topic 11. ºÎÁ¤¸Æ -------- 287
11-1. Ç׺ÎÁ¤¸ÆÁ¦ -------- 287
11-2. ºÎÁ¤¸ÆÀÇ ¾à¹°¿ä¹ý: Overview -------- 301
Topic 12. ½ÉºÎÀü -------- 302
[SPECIAL REVIEW] ARNI (Angiotensin Receptor Neprilysin Inhibitor) -------- 340
Topic 13. ÇãÇ÷¼º ½ÉÁúȯ -------- 348
[SUPPLEMENT] ÇãÇ÷¼º ½ÉÁúȯ ¿ä¾à -------- 351

PART 3. Ç÷¾×
Chapter 01. [Drug Class Revi
ew] Ç÷¾×°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. Ç÷¾×Á¦Á¦ -------- 384
Topic 2. ÁöÇ÷Á¦Á¦ -------- 389
Topic 3. Á¶Ç÷¼ºÀåÀÎÀÚ -------- 397

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ö°áÇ̺óÇ÷ -------- 406
Topic 5. °Å´ëÀûÇ÷¸ð±¸ºóÇ÷ -------- 418
Topic 6. ¸é¿ªÇ÷¼ÒÆÇ°¨¼ÒÁõ -------- 424

PART 4. È£Èí±â/¾Ë·¹¸£±â
Chapter 01. [Drug Class Review] È£Èí±â/¾Ë·¹¸£±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÁøÇØ°Å´ãÁ¦ -------- 436
1-1. ÁøÇØÁ¦ -------- 436
1-2. °Å´ãÁ¦ -------- 442
Topic 2. ±â°üÁöÈ®ÀåÁ¦ -------- 453
Topic 3. ±¹¼Ò ½ºÅ×·ÎÀ̵å: ÈíÀÔ ½ºÅ×·ÎÀ̵å -------- 462

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ¸¸¼º ±âħ -------- 468
[SUPPLEMENT] ¸¸¼º ±âħ: ÁÖ¿ä ¿øÀÎ Áúȯº° Ä¡·á -------- 475
Topic 5. ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD) -------- 484
[SUPPLEMENT] GOLD °¡À̵å¶óÀÎÀÇ º¯È­ -------- 496
[SUPPLEMENT] ¸¸¼ºÆó¼â¼º ÆóÁúȯ(COPD): ±Þ¼º¾ÇÈ­ -------- 503
[SUPPLEMENT] Phosphodiesterase4 (PDE4) ¾ïÁ¦Á¦ -------- 514
Topic 6. õ½Ä(Asthma) -------- 516
Topic 7. ¾Ë·¹¸£±â ºñ¿°(Allergic rhinitis) -------- 529

PART 5. ¼ÒÈ­±â
Chapter 01. [Drug Class Review] ¼ÒÈ­±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. À§½Äµµ¿ª·ùÁúȯ/¼ÒÈ­¼º ±Ë¾ç Ä¡·áÁ¦ -------- 552
1-1. ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦(Proton pump inhibitor, PPI) -------- 558
1-2. À§»êºÐºñ¾ïÁ¦Á¦: Potassium-Competitive Acid Blockers(PCAB) -------- 572
1-3. À§»êºÐºñ¾ïÁ¦Á¦: Histamine-2 receptor antagonist(H2RA) -------- 577
1-4. Á¦»êÁ¦ -------- 585
1-5. Á¡¸·º¸È£Á¦(Coating agents)/±âŸ ¹æ¾îÀÎÀÚ Áõ°­¾àÁ¦ -------- 591
Topic 2. À§Àå°ü¿îµ¿ÃËÁøÁ¦(Prokinetics) -------- 599
Topic 3. Ç×±¸ÅäÁ¦(Anti-emetics) -------- 610
Topic 4. Áö»çÁ¦(Anti-diarrheal agents) -------- 623
Topic 5. º¯ºñ, ¿ÏÇÏÁ¦ -------- 629

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 6. ½Ä¿åºÎÁø/½Ä¿åÃËÁøÁ¦(appetite stimulants) -------- 644
Topic 7. ¸¸¼º º¯ºñ -------- 647
Topic 8. À§½Äµµ¿ª·ùÁúȯ -------- 650
Topic 9. ¼ÒÈ­¼º ±Ë¾ç/Ç︮ÄÚ¹ÚÅÍ °¨¿° -------- 664
[SUPPLEMENT] ¼ÒÈ­¼º ±Ë¾ç: NSAIDs ¿¬°ü ±Ë¾ç -------- 668
Topic 10. ±â´É¼º À§ÀåÀå¾Ö -------- 683
10-1. ±â´É¼º ¼ÒÈ­ºÒ·®Áõ -------- 683
10-2. °ú¹Î´ëÀåÁõÈıº -------- 692
Topic 11. ¿°Áõ¼º ÀåÁúȯ -------- 706
[SPECIAL REVIEW] ±Ë¾ç¼º ´ëÀå¿° vs. Å©·Ðº´ -------- 709
Topic 12. ¸¸¼º BÇü °£¿° -------- 725
Topic 13. ¸¸¼º CÇü °£¿° -------- 734
[SPECIAL REVIEW] Pan-genotypic DAA regimens -pentin, pregabalin -------- 292
Topic 2. µµÆĹΠ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 297
2-1. Ç×Á¤½Åº´Á¦ -------- 297
Topic 3. Adrenergic, serotonergic ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 315
3-1. Ç׿ì¿ïÁ¦ -------- 315
3-2. ±âºÐÁ¶ÀýÁ¦ -------- 334
Topic 4. ±âŸ -------- 338
4-1. Á¤½ÅÀÚ±ØÁ¦ -------- 338

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 5. ÆíµÎÅë -------- 346
Topic 6. ¶³¸²/ÆÄŲ½¼º´ -------- 370
Topic 7. ¹ßÀÛ(seizure)/³úÀüÁõ(epilepsy) -------- 390
Topic 8. ¾îÁö·³Áõ -------- 398
Topic 9. Ä¡¸Å -------- 406
Topic 10. ºÒ¾ÈÀå¾Ö -------- 423
Topic 11. ¿ì¿ïÀå¾Ö -------- 435
Topic 12. ¼ö¸éÀå¾Ö -------- 448
Topic 13. ÁÖÀǷ°áÇÌ°úÀ×ÇൿÀå¾Ö(ADHD) -------- 470
Topic 14. Èí¿¬(±Ý¿¬¾à¹°) -------- 481

PART 9. ´« ±Í ÄÚ µÎ°æºÎ
Chapter 01. [Drug Class Review] ´«, ±Í, ÄÚ, µÎ°æºÎ¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ¿Ü¿ëÁ¦(Á¡¾ÈÁ¦) -------- 500
[SUPPLEMENT] ¾È¾àÀÇ ¿Ã¹Ù¸¥ »ç¿ë¹æ¹ý -------- 503
Topic 2. ¿Ü¿ëÁ¦(Á¡ÀÌÁ¦) -------- 506
[SUPPLEMENT] Á¡ÀÌÁ¦ÀÇ ¿Ã¹Ù¸¥ »ç¿ë¹æ¹ý -------- 507

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 3. ¿ÜÀ̵µ¿° -------- 510
Topic 4. ¾È±¸°ÇÁ¶Áõ -------- 515
Topic 5. °á¸·¿°: ¾Ë·¹¸£±â°á¸·¿°À» Áß½ÉÀ¸·Î -------- 528
Topic 6. ³ì³»Àå -------- 536

PART 10. ±Ù°ñ°Ý°è/·ù¸¶Æ¼½º
Chapter 01. [Drug Class Review] ±Ù°ñ°Ý¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ±ÙÀÌ¿ÏÁ¦ -------- 548

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 2. ·ù¸¶Æ¼½º°üÀý¿° -------- 556
Topic 3. °ñ°üÀý¿° -------- 583
Topic 4. Åëdz -------- 595
Topic 5. Àü½ÅÈ«¹Ý·çǪ½º -------- 615

PART 11. ÇǺÎ
Chapter 01. [Drug Class Review] ÇǺο¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÇǺοܿëÁ¦: ±¹¼Ò ½ºÅ×·ÎÀ̵å Á¦Á¦(topical corticosteroid) -------- 624
Topic 2. ÇǺοܿëÁ¦: ±¹¼Ò ¸é¿ªÁ¶ÀýÁ¦(topical immunomodulator) -------- 631
Topic 3. ÇǺοܿëÁ¦: ±¹¼Ò Ç×»ýÁ¦(Ç×±ÕÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×Áø±ÕÁ¦) -------- 636

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ½ÀÁø -------- 642
4-1. ¾ÆÅäÇÇÇǺο° -------- 642
4-2. Áö·çÇǺο° -------- 650
Topic 5. °Ç¼± -------- 658
Topic 6. ¿©µå¸§ -------- 666
Topic 7. Å»¸ð -------- 679
------- 745

Vol. 2

PART 6. ³»ºÐºñ
Chapter 01. [Drug Class Review] ³»ºÐºñ¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ºÎ½Å°ÑÁú È£¸£¸ó/±æÇ×Á¦ -------- 4
Topic 2. »ý½Ä»ù È£¸£¸ó/±æÇ×Á¦ -------- 6
2-1. »ý½Ä»ù È£¸£¸ó -------- 6
2-2. »ý½Ä»ù È£¸£¸ó ±æÇ×Á¦ -------- 18

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 3. °©»ó»ù Áúȯ -------- 32
3-1. °©»ó»ù ±â´ÉÀúÇÏÁõ -------- 32
[Âü°í] °©»ó»ù ÁúȯÀ» ÀÌÇØÇϱâ À§ÇÑ ±âÃÊ -------- 32
3-2. °©»ó»ù ±â´ÉÇ×ÁøÁõ -------- 42
Topic 4. ´ç´¢º´ -------- 52
4-1. ´ç´¢º´: Ä¡·á ¹× ¾à¹°¿ä¹ý Overview -------- 52
4-2. ´ç´¢º´: ¾à¹°¿ä¹ý-°æ±¸Ç÷´ç°­ÇÏÁ¦ -------- 78
[SUPPLEMENT] Incretin °ü·Ã ¾à¹° -------- 87
4-3. ´ç´¢º´: ¾à¹°¿ä¹ý-ÁÖ»çÁ¦ -------- 96
Topic 5. ÀÌ»óÁöÁúÇ÷Áõ -------- 103
[SPECIAL REVIEW] PCSK9 (Proprotein convertase subtilisin-kexin type 9) ¾ïÁ¦Á¦ -------- 120
Topic 6. ºñ¸¸ -------- 121
[SPECIAL REVIEW] GLP-1 agonist: Liraglutide (Saxenda) -------- 130
Topic 7. °ñ´Ù°øÁõ -------- 142
[SPECIAL REVIEW] °ñ´Ù°øÁõ: ¾à¹°¿ä¹ý: Denosumab (RANKL ´ÜÀÏŬ·ÐÇ×ü) -------- 161
Topic 8. Æó°æ(¿©¼º°»³â±â ÁõÈıº) -------- 178
Topic 9. ³²¼º°»³â±â ÁõÈıº -------- 185

PART 7. ¿ä·Î»ý½Ä±â
Chapter 01. [Drug Class Review] ¿ä·Î»ý½Ä±â¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö¿¡ »ç¿ëµÇ´Â ¾à¹° -------- 197

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 2. ÇϺοä·ÎÁõ»ó/¹è´¢Àå¾Ö -------- 198
2-1. Àü¸³¼±ºñ´ëÁõ -------- 198
2-2. °ú¹Î¼º ¹æ±¤ -------- 215
[SPECIAL REVIEW] °ú¹Î¼º¹æ±¤: ¾à¹°¿ä¹ý: º£Å¸3 ¾Æµå·¹³¯¸° ¼ö¿ëü ÀÛ¿ëÁ¦: mirabegron -------- 220
2-3. ¿ä½Ç±Ý -------- 226
Topic 3. ³²¼º ¼º±â´ÉÀå¾Ö -------- 234
3-1. ¹ß±âºÎÀü -------- 234
3-2. Á¶·çÁõ -------- 246

PART 8. ½Å°æ/Á¤½Å
Chapter 01. [Drug Class Review] ½Å°æ/Á¤½Å°è¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. GABA ¹× Glutamate¼º ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 256
[Âü°í] GABA/Glutamate -------- 256
1-1. Benzodiazepine -------- 258
1-2. Barbiturate -------- 269
1-3. Ç׳úÀüÁõÁ¦ -------- 275
[SPECIAL REVIEW] Gabapentenoids: gabapentin, pregabalin -------- 292
Topic 2. µµÆĹΠ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 297
2-1. Ç×Á¤½Åº´Á¦ -------- 297
Topic 3. Adrenergic, serotonergic ½Å°æÀü´Þ °ü·Ã¾à¹° -------- 315
3-1. Ç׿ì¿ïÁ¦ -------- 315
3-2. ±âºÐÁ¶ÀýÁ¦ -------- 334
Topic 4. ±âŸ -------- 338
4-1. Á¤½ÅÀÚ±ØÁ¦
-------- 338

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 5. ÆíµÎÅë -------- 346
Topic 6. ¶³¸²/ÆÄŲ½¼º´ -------- 370
Topic 7. ¹ßÀÛ(seizure)/³úÀüÁõ(epilepsy) -------- 390
Topic 8. ¾îÁö·³Áõ -------- 398
Topic 9. Ä¡¸Å -------- 406
Topic 10. ºÒ¾ÈÀå¾Ö -------- 423
Topic 11. ¿ì¿ïÀå¾Ö -------- 435
Topic 12. ¼ö¸éÀå¾Ö -------- 448
Topic 13. ÁÖÀǷ°áÇÌ°úÀ×ÇൿÀå¾Ö(ADHD) -------- 470
Topic 14. Èí¿¬(±Ý¿¬¾à¹°) -------- 481

PART 9. ´« ¤ý ±Í ¤ý ÄÚ ¤ý µÎ°æºÎ
Chapter 01. [Drug Class Review] ´«, ±Í, ÄÚ, µÎ°æºÎ¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ¿Ü¿ëÁ¦(Á¡¾ÈÁ¦) -------- 500
[SUPPLEMENT] ¾È¾àÀÇ ¿Ã¹Ù¸¥ »ç¿ë¹æ¹ý -------- 503
Topic 2. ¿Ü¿ëÁ¦(Á¡ÀÌÁ¦) -------- 506
[SUPPLEMENT] Á¡ÀÌÁ¦ÀÇ ¿Ã¹Ù¸¥ »ç¿ë¹æ¹ý -------- 507

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 3. ¿ÜÀ̵µ¿° -------- 510
Topic 4. ¾È±¸°ÇÁ¶Áõ -------- 515
Topic 5. °á¸·¿°: ¾Ë·¹¸£±â°á¸·¿°À» Áß½ÉÀ¸·Î -------- 528
Topic 6. ³ì³»Àå -------- 536

PART 10. ±Ù°ñ°Ý°è/·ù¸¶Æ¼½º
Chapter 01. [Drug Class Review] ±Ù°ñ°Ý¿¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ±ÙÀÌ¿ÏÁ¦ -------- 548

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 2. ·ù¸¶Æ¼½º°üÀý¿° -------- 556
Topic 3. °ñ°üÀý¿° -------- 583
Topic 4. Åëdz -------- 595
Topic 5. Àü½ÅÈ«¹Ý·çǪ½º -------- 615

PART 11. ÇǺÎ
Chapter 01. [Drug Class Review] ÇǺο¡ ÁÖ·Î »ç¿ëµÇ´Â ¾à¹°
Topic 1. ÇǺοܿëÁ¦: ±¹¼Ò ½ºÅ×·ÎÀ̵å Á¦Á¦(topical corticosteroid) -------- 624
Topic 2. ÇǺοܿëÁ¦: ±¹¼Ò ¸é¿ªÁ¶ÀýÁ¦(topical immunomodulator) -------- 631
Topic 3. ÇǺοܿëÁ¦: ±¹¼Ò Ç×»ýÁ¦(Ç×±ÕÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×Áø±ÕÁ¦) -------- 636

Chapter 02. Áõ»ó/Áúȯº° ¾àó¹æÀÇ Á¤¼®
Topic 4. ½ÀÁø -------- 642
4-1. ¾ÆÅäÇÇÇǺο° -------- 642
4-2. Áö·çÇǺο° -------- 650
Topic 5. °Ç¼± -------- 658
Topic 6. ¿©µå¸§ -------- 666
Topic 7. Å»¸ð -------- 679

º»¹®Áß¿¡¼­

ÀÌ Ã¥ÀÇ ÁýÇÊ µ¿±â´Â ÇѸ¶µð·Î »ó´ë¸¦ ¾Ë°í ³ª¸¦ ¾Ë¸é ¹é ¹ø ½Î¿öµµ À§Å·ÓÁö ¾Ê´Ù´Â "ÁöÇÇÁö±â ¹éÀüºÒÅÂ" Á¤½ÅÀÔ´Ï´Ù.
ÀÇ»ç ÀÔÀå¿¡¼­ "ÁöÇÇ"´Â ´Ù½º·Á¾ß ÇÒ Áúº´ÀÇ Á¤Ã¼¸¦ Á¦´ë·Î ÆľÇÇØ¾ß ÇÑ´Ù´Â Àǹ̰ÚÁö¿ä. ¹Ý¸é "Áö±â"´Â ³» ¼Õ¿¡ Áã¾îÁø ¹«±â¸¦ Á¦´ë·Î ¾Ë°í ´É¼÷ÇÏ°Ô »ç¿ëÇØ¾ß ÇÑ´Ù´Â ¶æÀ¸·Î ´Ù°¡¿É´Ï´Ù.
È°¿ë °¡´ÉÇÑ ¹«±â¶õ ¿Ü°ú°è Àǻ翡°Õ ¼ö¼úÀÏ Å×°í, ³»°ú°è Àǻ翡°Ô´Â ´Ü¿¬ÄÚ ¾à¹°ÀÌ°ÚÁÒ.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ ¾øÀÌ ¾àÀ» ó¹æÇÏ°í ½ÍÁö ¾Ê¾Ò½À´Ï´Ù. ÇÏÁö¸¸ ¹«¼öÈ÷ ¸¹Àº ¾àÀÌ Á¸ÀçÇϱ⿡ ÀÌµé ¾àÀÇ Á¤Ã¼¸¦ ÇϳªÇϳª ÆľÇÇÑ´Ù´Â °Ç ¹«Ã´À̳ª ¹ö°Å¿î °úÁ¤ÀÏ °Ì´Ï´Ù. ¾àÀº ´ë°³ ÀÛ¿ë±âÀüÀ̳ª »ç¿ë ¸ñÀû¿¡ µû¶ó ƯÁ¤ ¾à¹°±º("Drug class")À¸·Î ºÐ·ùµÇ±â ¶§¹®¿¡ "Drug class"º°·Î ¹­¾î¼­ Ư¡À» ÆľÇÇÑ´Ù¸é ¼Ò±âÀÇ ¸ñÀûÀº ´Þ¼ºÇÏ´Â ¼ÀÀÌ°ÚÁö¿ä. ÀÌ°Ô ¹Ù·Î º» Ã¥ÀÌ Ãß±¸ÇÏ´Â "Drug class review"ÀÔ´Ï´Ù.
ÇÏÁö¸¸ º» Ã¥Àº ´Ü¼øÈ÷ ¾à¿¡ ´ëÇÑ Á¤º¸¸¸À» Á¦°øÇϱâ À§ÇÑ Ã¥Àº ¾Æ´Õ´Ï´Ù.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ¿¡¼­ ÇÑ¹ß ´õ ³ª¾Æ°¡ °¡À̵å¶óÀÎÀ̳ª ±Ù°Å ±â¹ÝÀ¸·Î ¾àÀ» ó¹æÇÏ´Â ½ÇÀüÁöħÀ» Á¦½ÃÇÏ´Â °ÍÀÌ ÀÌ Ã¥ÀÇ ±Ã±ØÀûÀÎ ÁöÇâÁ¡ÀÔ´Ï´Ù. ÀÌ°ÍÀÌ ¹Ù·Î "Real world prescription"À̶ó´Â ºÎÁ¦¿¡ ´ã±ä ÀǹÌÀÔ´Ï´Ù.
ÀÇ»ç·Î »ì¾Æ°¡´Â µ¿¾È ¶¼·Á¾ß ¶¿ ¼ö ¾ø´Â °Ô ¾àÀ̱⿡ ¾à¿¡ ´ëÇÑ °í¹ÎÀº Áö¼ÓµÉ ¼ö¹Û¿¡ ¾ø½À´Ï´Ù.
±×·¸Áö¸¸ ²÷ÀÓ¾øÀÌ ½Å¾àÀÌ ½ñ¾ÆÁ® ³ª¿À°í ±âÁ¸ ¾àÀÇ ¿ëµµµµ »õ·Ó°Ô Á¤ÀǵǴ µî ¾à¿¡ ´ëÇÑ ÃÖ½ÅÁ¤º¸¸¦ ¾÷µ¥ÀÌÆ®Çϱâ´Â ½±Áö ¾Ê½À´Ï´Ù.
º» Ã¥ÀÌ ¾à¿¡ ´ëÇÑ À¯¿ëÇÑ Âü°í¼­·Î ÀÚ¸®¸Å±èÇÏ¿© ¾àÀ» Á¦´ë·Î ¾Ë°í º¸´Ù ¹Ù¸¥ ó¹æÀ» ³»¸®´Â µ¥ ÀÏÁ¶ÇßÀ¸¸é ÇÏ´Â ¹Ù¶÷ÀÔ´Ï´Ù.

(/ '¼­¹®' Áß¿¡¼­)

[¼­¹®]
Ã¥À» º¸½Ã±â Àü¿¡

ÀÌ Ã¥ÀÇ ÁýÇÊ µ¿±â´Â ÇѸ¶µð·Î »ó´ë¸¦ ¾Ë°í ³ª¸¦ ¾Ë¸é ¹é ¹ø ½Î¿öµµ À§Å·ÓÁö ¾Ê´Ù´Â "ÁöÇÇÁö±â ¹éÀüºÒÅÂ" Á¤½ÅÀÔ´Ï´Ù.
ÀÇ»ç ÀÔÀå¿¡¼­ "ÁöÇÇ"´Â ´Ù½º·Á¾ß ÇÒ Áúº´ÀÇ Á¤Ã¼¸¦ Á¦´ë·Î ÆľÇÇØ¾ß ÇÑ´Ù´Â Àǹ̰ÚÁö¿ä. ¹Ý¸é "Áö±â"´Â ³» ¼Õ¿¡ Áã¾îÁø ¹«±â¸¦ Á¦´ë·Î ¾Ë°í ´É¼÷ÇÏ°Ô »ç¿ëÇØ¾ß ÇÑ´Ù´Â ¶æÀ¸·Î ´Ù°¡¿É´Ï´Ù.
È°¿ë °¡´ÉÇÑ ¹«±â¶õ ¿Ü°ú°è Àǻ翡°Õ ¼ö¼úÀÏ Å×°í, ³»°ú°è Àǻ翡°Ô´Â ´Ü¿¬ÄÚ ¾à¹°ÀÌ°ÚÁÒ.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ ¾øÀÌ ¾àÀ» ó¹æÇÏ°í ½ÍÁö ¾Ê¾Ò½À´Ï´Ù. ÇÏÁö¸¸ ¹«¼öÈ÷ ¸¹Àº ¾àÀÌ Á¸ÀçÇϱ⿡ ÀÌµé ¾àÀÇ Á¤Ã¼¸¦ ÇϳªÇϳª ÆľÇÇÑ´Ù´Â °Ç ¹«Ã´À̳ª ¹ö°Å¿î °úÁ¤ÀÏ °Ì´Ï´Ù. ¾àÀº ´ë°³ ÀÛ¿ë±âÀüÀ̳ª »ç¿ë ¸ñÀû¿¡ µû¶ó ƯÁ¤ ¾à¹°±º("Drug class")À¸·Î ºÐ·ùµÇ±â ¶§¹®¿¡ "Drug class"º°·Î ¹­¾î¼­ Ư¡À» ÆľÇÇÑ´Ù¸é ¼Ò±âÀÇ ¸ñÀûÀº ´Þ¼ºÇÏ´Â ¼ÀÀÌ°ÚÁö¿ä. ÀÌ°Ô ¹Ù·Î º» Ã¥ÀÌ Ãß±¸ÇÏ´Â "Drug class review"ÀÔ´Ï´Ù.
ÇÏÁö¸¸ º» Ã¥Àº ´Ü¼øÈ÷ ¾à¿¡ ´ëÇÑ Á¤º¸¸¸À» Á¦°øÇϱâ À§ÇÑ Ã¥Àº ¾Æ´Õ´Ï´Ù.
¾à¿¡ ´ëÇÑ Æ÷°ýÀû ÀÌÇØ¿¡¼­ ÇÑ¹ß ´õ ³ª¾Æ°¡ °¡À̵å¶óÀÎÀ̳ª ±Ù°Å ±â¹ÝÀ¸·Î ¾àÀ» ó¹æÇÏ´Â ½ÇÀüÁöħÀ» Á¦½ÃÇÏ´Â °ÍÀÌ ÀÌ Ã¥ÀÇ ±Ã±ØÀûÀÎ ÁöÇâÁ¡ÀÔ´Ï´Ù. ÀÌ°ÍÀÌ ¹Ù·Î "Real world prescription"À̶ó´Â ºÎÁ¦¿¡ ´ã±ä ÀǹÌÀÔ´Ï´Ù.
ÀÇ»ç·Î »ì¾Æ°¡´Â µ¿¾È ¶¼·Á¾ß ¶¿ ¼ö ¾ø´Â °Ô ¾àÀ̱⿡ ¾à¿¡ ´ëÇÑ °í¹ÎÀº Áö¼ÓµÉ ¼ö¹Û¿¡ ¾ø½À´Ï´Ù.
±×·¸Áö¸¸ ²÷ÀÓ¾øÀÌ ½Å¾àÀÌ ½ñ¾ÆÁ® ³ª¿À°í ±âÁ¸ ¾àÀÇ ¿ëµµµµ »õ·Ó°Ô Á¤ÀǵǴ µî ¾à¿¡ ´ëÇÑ ÃÖ½ÅÁ¤º¸¸¦ ¾÷µ¥ÀÌÆ®Çϱâ´Â ½±Áö ¾Ê½À´Ï´Ù.
º» Ã¥ÀÌ ¾à¿¡ ´ëÇÑ À¯¿ëÇÑ Âü°í¼­·Î ÀÚ¸®¸Å±èÇÏ¿© ¾àÀ» Á¦´ë·Î ¾Ë°í º¸´Ù ¹Ù¸¥ ó¹æÀ» ³»¸®´Â µ¥ ÀÏÁ¶ÇßÀ¸¸é ÇÏ´Â ¹Ù¶÷ÀÔ´Ï´Ù.

2020³â 5¿ù 31ÀÏ
ÀúÀÚ ÀÌ»óºÀ

ÀúÀÚ¼Ò°³

ÀÌ»óºÀ [Àú] ½ÅÀ۾˸² SMS½Åû
»ý³â¿ùÀÏ -

ÇØ´çÀÛ°¡¿¡ ´ëÇÑ ¼Ò°³°¡ ¾ø½À´Ï´Ù.

Àü°øµµ¼­/´ëÇб³Àç ºÐ¾ß¿¡¼­ ¸¹Àº ȸ¿øÀÌ ±¸¸ÅÇÑ Ã¥

    ¸®ºä

    0.0 (ÃÑ 0°Ç)

    100ÀÚÆò

    ÀÛ¼º½Ã À¯ÀÇ»çÇ×

    ÆòÁ¡
    0/100ÀÚ
    µî·ÏÇϱâ

    100ÀÚÆò

    10.0
    (ÃÑ 0°Ç)

    ÆǸÅÀÚÁ¤º¸

    • ÀÎÅÍÆÄÅ©µµ¼­¿¡ µî·ÏµÈ ¿ÀǸ¶ÄÏ »óÇ°Àº ±× ³»¿ë°ú Ã¥ÀÓÀÌ ¸ðµÎ ÆǸÅÀÚ¿¡°Ô ÀÖÀ¸¸ç, ÀÎÅÍÆÄÅ©µµ¼­´Â ÇØ´ç »óÇ°°ú ³»¿ë¿¡ ´ëÇØ Ã¥ÀÓÁöÁö ¾Ê½À´Ï´Ù.

    »óÈ£

    (ÁÖ)±³º¸¹®°í

    ´ëÇ¥ÀÚ¸í

    ¾Èº´Çö

    »ç¾÷ÀÚµî·Ï¹øÈ£

    102-81-11670

    ¿¬¶ôó

    1544-1900

    ÀüÀÚ¿ìÆíÁÖ¼Ò

    callcenter@kyobobook.co.kr

    Åë½ÅÆǸž÷½Å°í¹øÈ£

    01-0653

    ¿µ¾÷¼ÒÀçÁö

    ¼­¿ïƯº°½Ã Á¾·Î±¸ Á¾·Î 1(Á¾·Î1°¡,±³º¸ºôµù)

    ±³È¯/ȯºÒ

    ¹ÝÇ°/±³È¯ ¹æ¹ý

    ¡®¸¶ÀÌÆäÀÌÁö > Ãë¼Ò/¹ÝÇ°/±³È¯/ȯºÒ¡¯ ¿¡¼­ ½Åû ¶Ç´Â 1:1 ¹®ÀÇ °Ô½ÃÆÇ ¹× °í°´¼¾ÅÍ(1577-2555)¿¡¼­ ½Åû °¡´É

    ¹ÝÇ°/±³È¯°¡´É ±â°£

    º¯½É ¹ÝÇ°ÀÇ °æ¿ì Ãâ°í¿Ï·á ÈÄ 6ÀÏ(¿µ¾÷ÀÏ ±âÁØ) À̳»±îÁö¸¸ °¡´É
    ´Ü, »óÇ°ÀÇ °áÇÔ ¹× °è¾à³»¿ë°ú ´Ù¸¦ °æ¿ì ¹®Á¦Á¡ ¹ß°ß ÈÄ 30ÀÏ À̳»

    ¹ÝÇ°/±³È¯ ºñ¿ë

    º¯½É ȤÀº ±¸¸ÅÂø¿À·Î ÀÎÇÑ ¹ÝÇ°/±³È¯Àº ¹Ý¼Û·á °í°´ ºÎ´ã
    »óÇ°À̳ª ¼­ºñ½º ÀÚüÀÇ ÇÏÀÚ·Î ÀÎÇÑ ±³È¯/¹ÝÇ°Àº ¹Ý¼Û·á ÆǸÅÀÚ ºÎ´ã

    ¹ÝÇ°/±³È¯ ºÒ°¡ »çÀ¯

    ·¼ÒºñÀÚÀÇ Ã¥ÀÓ ÀÖ´Â »çÀ¯·Î »óÇ° µîÀÌ ¼Õ½Ç ¶Ç´Â ÈÑ¼ÕµÈ °æ¿ì
    (´ÜÁö È®ÀÎÀ» À§ÇÑ Æ÷Àå ÈѼÕÀº Á¦¿Ü)

    ·¼ÒºñÀÚÀÇ »ç¿ë, Æ÷Àå °³ºÀ¿¡ ÀÇÇØ »óÇ° µîÀÇ °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì
    ¿¹) È­ÀåÇ°, ½ÄÇ°, °¡ÀüÁ¦Ç°(¾Ç¼¼¼­¸® Æ÷ÇÔ) µî

    ·º¹Á¦°¡ °¡´ÉÇÑ »óÇ° µîÀÇ Æ÷ÀåÀ» ÈѼÕÇÑ °æ¿ì
    ¿¹) À½¹Ý/DVD/ºñµð¿À, ¼ÒÇÁÆ®¿þ¾î, ¸¸È­Ã¥, ÀâÁö, ¿µ»ó È­º¸Áý

    ·½Ã°£ÀÇ °æ°ú¿¡ ÀÇÇØ ÀçÆǸŰ¡ °ï¶õÇÑ Á¤µµ·Î °¡Ä¡°¡ ÇöÀúÈ÷ °¨¼ÒÇÑ °æ¿ì

    ·ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚº¸È£¿¡ °üÇÑ ¹ý·üÀÌ Á¤ÇÏ´Â ¼ÒºñÀÚ Ã»¾àöȸ Á¦ÇÑ ³»¿ë¿¡ ÇØ´çµÇ´Â °æ¿ì

    »óÇ° Ç°Àý

    °ø±Þ»ç(ÃâÆÇ»ç) Àç°í »çÁ¤¿¡ ÀÇÇØ Ç°Àý/Áö¿¬µÉ ¼ö ÀÖÀ½

    ¼ÒºñÀÚ ÇÇÇغ¸»ó
    ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó

    ·»óÇ°ÀÇ ºÒ·®¿¡ ÀÇÇÑ ±³È¯, A/S, ȯºÒ, Ç°Áúº¸Áõ ¹× ÇÇÇغ¸»ó µî¿¡ °üÇÑ »çÇ×Àº ¼ÒºñÀÚºÐÀïÇØ°á ±âÁØ (°øÁ¤°Å·¡À§¿øȸ °í½Ã)¿¡ ÁØÇÏ¿© 󸮵Ê

    ·´ë±Ý ȯºÒ ¹× ȯºÒÁö¿¬¿¡ µû¸¥ ¹è»ó±Ý Áö±Þ Á¶°Ç, ÀýÂ÷ µîÀº ÀüÀÚ»ó°Å·¡ µî¿¡¼­ÀÇ ¼ÒºñÀÚ º¸È£¿¡ °üÇÑ ¹ý·ü¿¡ µû¶ó ó¸®ÇÔ

    (ÁÖ)KGÀ̴Ͻýº ±¸¸Å¾ÈÀü¼­ºñ½º¼­ºñ½º °¡ÀÔ»ç½Ç È®ÀÎ

    (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º´Â ȸ¿ø´ÔµéÀÇ ¾ÈÀü°Å·¡¸¦ À§ÇØ ±¸¸Å±Ý¾×, °áÁ¦¼ö´Ü¿¡ »ó°ü¾øÀÌ (ÁÖ)ÀÎÅÍÆÄÅ©Ä¿¸Ó½º¸¦ ÅëÇÑ ¸ðµç °Å·¡¿¡ ´ëÇÏ¿©
    (ÁÖ)KGÀ̴Ͻýº°¡ Á¦°øÇÏ´Â ±¸¸Å¾ÈÀü¼­ºñ½º¸¦ Àû¿ëÇÏ°í ÀÖ½À´Ï´Ù.

    ¹è¼Û¾È³»

    • ±³º¸¹®°í »óÇ°Àº Åùè·Î ¹è¼ÛµÇ¸ç, Ãâ°í¿Ï·á 1~2Àϳ» »óÇ°À» ¹Þ¾Æ º¸½Ç ¼ö ÀÖ½À´Ï´Ù.

    • Ãâ°í°¡´É ½Ã°£ÀÌ ¼­·Î ´Ù¸¥ »óÇ°À» ÇÔ²² ÁÖ¹®ÇÒ °æ¿ì Ãâ°í°¡´É ½Ã°£ÀÌ °¡Àå ±ä »óÇ°À» ±âÁØÀ¸·Î ¹è¼ÛµË´Ï´Ù.

    • ±ººÎ´ë, ±³µµ¼Ò µî ƯÁ¤±â°üÀº ¿ìü±¹ Åù踸 ¹è¼Û°¡´ÉÇÕ´Ï´Ù.

    • ¹è¼Ûºñ´Â ¾÷ü ¹è¼Ûºñ Á¤Ã¥¿¡ µû¸¨´Ï´Ù.

    • - µµ¼­ ±¸¸Å ½Ã 15,000¿ø ÀÌ»ó ¹«·á¹è¼Û, 15,000¿ø ¹Ì¸¸ 2,500¿ø - »óÇ°º° ¹è¼Ûºñ°¡ ÀÖ´Â °æ¿ì, »óÇ°º° ¹è¼Ûºñ Á¤Ã¥ Àû¿ë